Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet

Giuseppe Derosa, Amedeo Mugellini, Leonardina Ciccarelli, Roberto Fogari

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: The aim of this study was to assess obese patients with hypercholesterolemia who were prescribed a standardized diet, comparing the action of orlistat, fluvastatin, orlistat with fluvastatin, and placebo on anthropometric measurements, blood pressure (BP), and lipid profile. Methods: This was a 1-year, randomized, double-blind, placebo-controlled trial. The patients were prescribed a controlled-energy diet and were randomly allocated to receive placebo, orlistat 120 mg TID (O group), fluvastatin 80 mg/d (F group), or orlistat 120 mg TID with fluvastatin 80 mg/d (OF group). Clinical measurements (body weight, body mass index [BMI], waist circumference, and BP) and lipid profile assessments (total cholesterol [TC], low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], and triglycerides [TGs]) were performed at baseline and after 6 months and 1 year of treatment. Results: The study included 99 obese patients with hypercholesterolemia (48 men and 51 women; mean [SD] age, 51 [9] years). There were no significant differences between groups in baseline demographic, BP, or plasma lipid values. Three patients dropped out (2 women in the O group and 1 man in the OF group) due to adverse events related to orlistat treatment, including gastrointestinal events (oily spotting and fecal urgency). Ninety-six patients completed the study. There were significant differences from baseline (mean [SD]) in BMI, waist circumference reduction (WCR), and body weight loss (BWL) at 6 months in the OF group (29.9 [1.1] kg/m 2, 2.7 [0.8] cm, and 7.4 [0.9] kg, respectively; all P <0.05), and in BMI, WCR, and BWL at 1 year in the O group (29.0 [1.0] kg/m 2, 3.0 [1.0] cm, and 8.6 [1.0] kg, respectively; all P <0.02), the F group (29.3 [1.6] kg/m 2, 2.4 [1.0] cm, and 8.0 [1.0] kg, respectively; all P <0.05), and the OF group (28.4 [0.6] kg/m 2, 4.0 [0.6] cm, and 11.4 [1.0] kg, respectively; all P <0.01). Significant reductions from baseline in systolic and diastolic BP were observed at 1 year in the O and F groups (all P <0.05) and the OF group (both P <0.01). At 6 months, there were significant reductions from baseline in TC and LDL-C in the F group (both P <0.05) and in TC, LDL-C, and TGs in the OF group (P <0.02, P <0.02, and P <0.05, respectively), as well as a significant increase in HDL-C in the OF group (P <0.02). At 1 year, there were significant reductions from baseline in TC in the O, F, and OF groups (P <0.05, P <0.02, and P <0.01, respectively), LDL-C (P <0.05, P <0.02, and P <0.01, respectively), and TGs (P <0.02, P <0.05, and P <0.02, respectively). Also at 1 year, HDL-C was significantly higher than baseline in the F and OF groups (P <0.02 and P <0.01, respectively). Conclusion: Improvements in clinical and lipid-profile parameters were found at 1 year with all 3 treatments.

Original languageEnglish
Pages (from-to)1107-1122
Number of pages16
JournalClinical Therapeutics
Volume25
Issue number4
DOIs
Publication statusPublished - Apr 1 2003

Keywords

  • Blood pressure
  • Diet
  • Dyslipidemia
  • Fluvastatin
  • Obesity
  • Orlistat

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet'. Together they form a unique fingerprint.

Cite this